Current management of gastrointestinal stromal tumors - A comprehensive review

International Journal of Surgery

Volumn 10, Issue 7, 2012, Pages 334-340

  Lai, Eric C H ^a   Lau, Stephanie H Y ^a   Lau, Wan Yee ^a  

^a Prince of Wales Hospital   (Hong Kong)

Author keywords

Gastrointestinal stromal tumors; GIST; Imatinib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

IMATINIB; STEM CELL FACTOR; SUNITINIB;

ABDOMINAL PAIN; ADJUVANT THERAPY; ANEMIA; CANCER RECURRENCE; CANCER SURGERY; CLINICAL FEATURE; DIARRHEA; DRUG DOSE INCREASE; DRUG ERUPTION; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GRANULOCYTOPENIA; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIORBITAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; THORAX PAIN; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PIPERAZINES; PYRIMIDINES; PYRROLES;

EID: 84864316078     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2012.05.007     Document Type: Review

References (74)

1. Nilsson B., Bümming P., Meis-Kindblom J.M., Odén A., Dortok A., Gustavsson B., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 2005, 103:821-829.
2. Tran T., Davila J.A., El-Serag H.B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005, 100:162-168.
3. Tryggvason G., Gíslason H.G., Magnússon M.K., Jónasson J.G. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005, 117:289-293.
4. Perez E.A., Livingstone A.S., Franceschi D., Rocha-Lima C., Lee D.J., Hodgson N., et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006, 202:623-629.
5. Machado-Aranda D., Malamet M., Chang Y.J., Jacobs M.J., Ferguson L., Silapaswan S., et al. Prevalence and management of gastrointestinal stromal tumors. Am Surg 2009, 75:55-60.
6. Monges G., Bisot-Locard S., Blay J.Y., Bouvier A.M., Urbieta M., Coindre J.M., et al. The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists. Bull Cancer 2010, 97:E16-E22.
7. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83.
8. Bucher P., Egger J.F., Gervaz P., Ris F., Weintraub D., Villiger P., et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 2006, 32:310-314.
9. Dematteo R.P., Gold J.S., Saran L., Gönen M., Liau K.H., Maki R.G., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008, 112:608-615.
10. Miettinen M., Sobin L.H., Lasota J. Gastrointestinal stromal tumors presenting as omental masses-a clinicopathologic analysis of 95 cases. Am J Surg Pathol 2009, 33:1267-1275.
11. Sarlomo-Rikala M., Kovatich A.J., Barusevicius A., Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specifi c than CD34. Mod Pathol 1998, 11:728-734.
12. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001, 61:8118-8121.
13. Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33:459-465.
14. Blay P., Astudillo A., Buesa J.M., Campo E., Abad M., García-García J., et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 2004, 10:4089-4095.
15. Rubin B.P., Blanke C.D., Demetri G.D., Dematteo R.P., Fletcher C.D., Goldblum J.R., et al. Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med 2010, 134:165-170.
16. Mazur M.T., Clark H.B. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983, 7(6):507-519.
17. Kindblom L.G., Remotti H.E., Aldenborg F., Meis-Kindblom J.M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998, 152:1259-1269.
18. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
19. Lasota J., Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006, 23:91-102.
20. Lasota J., Corless C.L., Heinrich M.C., Debiec-Rychter M., Sciot R., Wardelmann E., et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 2008, 21:476-484.
21. McAuliffe J.C., Wang W.L., Pavan G.M., Pricl S., Yang D., Chen S.S., et al. Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors. Mol Oncol 2008, 2:161-163.
22. DeMatteo R.P., Lewis J.J., Leung D., Mudan S.S., Woodruff J.M., Brennan M.F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51-58.
23. Bümming P., Ahlman H., Andersson J., Meis-Kindblom J.M., Kindblom L.G., Nilsson B. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006, 93:836-843.
24. Ghanem N., Altehoefer C., Furtwängler A., Winterer J., Schäfer O., Springer O., et al. Computed tomography in gastrointestinal stromal tumors. Eur Radiol 2003, 13:1669-1678.
25. Horton K.M., Juluru K., Montogomery E., Fishman E.K. Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation. J Comput Assist Tomogr 2004, 28:811-817.
26. Gong J.S., Zuo M., Yang P., Zang D., Zhang Y., Xia L., et al. Value of CT in the diagnosis and follow-up of gastrointestinal stromal tumors. Clin Imaging 2008, 32:172-177.
27. Levy A.D., Remotti H.E., Thompson W.M., Sobin L.H., Miettinen M. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2003, 23:283-304.
28. Levy A.D., Remotti H.E., Thompson W.M., Sobin L.H., Miettinen M. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation. AJR Am J Roentgenol 2003, 180:1607-1612.
29. Hasegawa S., Semelka R.C., Noone T.C., Woosley J.T., Marcos H.B., Kenney P.J., et al. Gastric str omal sarcomas: correlation of MR imaging and histopathologic findings in nine patients. Radiology 1998, 208:591-595.
30. Sandrasegaran K., Rajesh A., Rushing D.A., Rydberg J., Akisik F.M., Henley J.D. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol 2005, 15:1407-1414.
31. Heinicke T., Wardelmann E., Sauerbruch T., Tschampa H.J., Glasmacher A., Palmedo H. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 2005, 25:4591-4594.
32. Holdsworth C.H., Badawi R.D., Manola J.B., Kijewski M.F., Israel D.A., Demetri G.D., et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 2007, 189:W324-W330.
33. Fuster D., Ayuso J.R., Poveda A., Cubedo R., Casado A., Martínez-Trufero J., et al. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study. Q J Nucl Med Mol Imaging 2011, 55:680-687.
34. Aparicio T., Boige V., Sabourin J.C., Crenn P., Ducreux M., Le Cesne A., et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004, 30:1098-1103.
35. Woodall C.E., Brock G.N., Fan J., Byam J.A., Scoggins C.R., McMasters K.M., et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg 2009, 144:670-678.
36. Keun Park C., Lee E.J., Kim M., Lim H.Y., Choi D.I., Noh J.H., et al. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 2008, 247:1011-1018.
37. Hohenberger P., Ronellenfitsch U., Oladeji O., Pink D., Ströbel P., Wardelmann E., et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg 2010, 97:1854-1859.
38. Rutkowski P., Bylina E., Wozniak A., Nowecki Z.I., Osuch C., Matlok M., et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011, 37:890-896.
39. Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002, 10:81-89.
40. Gold J.S., Gönen M., Gutiérrez A., Broto J.M., García-del-Muro X., Smyrk T.C., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009, 10:1045-1052.
41. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349.
42. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40:689-695. EORTC Soft Tissue and Bone Sarcoma Group.
43. Debiec-Rychter M., Sciot R., Le Cesne A., Schlemmer M., Hohenberger P., van Oosterom A.T., et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42:1093-1103. EORTC Soft Tissue and Bone Sarcoma Group, Italian Sarcoma GroupItalian Sarcoma Group, Australasian GastroIntestinal Trials GroupAustralasian GastroIntestinal Trials Group.
44. Heinrich M.C., Owzar K., Corless C.L., Hollis D., Borden E.C., Fletcher C.D., et al. Correlation of kinas genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008, 26:5360-5367.
45. Heinrich M.C., Maki R.G., Corless C.L., Antonescu C.R., Harlow A., Griffith D., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib resistant gastrointestinal stromal tumor. J Clin Oncol 2008, 26:5352-5359.
46. Nikfarjam M., Kimchi E., Shereef S., Gusani N.J., Jiang Y., Liang J., et al. Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy. J Gastrointest Surg 2008, 12:2023-2031.
47. Krajinovic K., Germer C.T., Agaimy A., Wünsch P.H., Isbert C. Outcome after resection of one hundred gastrointestinal stromal tumors. Dig Surg 2010, 27:313-319.
48. Chung J.C., Chu C.W., Cho G.S., Shin E.J., Lim C.W., Kim H.C., et al. Management and outcome of gastrointestinal stromal tumors of the duodenum. J Gastrointest Surg 2010, 14:880-883.
49. Beham A, Schaefer IM, Cameron S, von Hammerstein K, Füzesi L, Ramadori G, et al. Duodenal GIST: a single center experience. Int J Colorectal Dis, in press.
50. Nilsson B., Sjölund K., Kindblom L.G., Meis-Kindblom J.M., Bümming P., Nilsson O., et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007, 96:1656-1658.
51. Jiang W.Z., Guan G.X., Lu H.S., Yang Y.H., Kang D.Y., Huang H.G. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J Surg Oncol 2011, 104:760-764.
52. Dematteo R.P., Ballman K.V., Antonescu C.R., Maki R.G., Pisters P.W., Demetri G.D., et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
53. Andtbacka R.H., Ng C.S., Scaife C.L., Cormier J.N., Hunt K.K., Pisters P.W., et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007, 14:14-24.
54. Eisenberg B.L., Harris J., Blanke C.D., Demetri G.D., Heinrich M.C., Watson J.C., et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009, 99:42-47.
55. Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of radiation therapy oncology group 0132. Ann Surg Oncol, in press.
56. Sjölund K., Andersson A., Nilsson E., Nilsson O., Ahlman H., Nilsson B. Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability. World J Surg 2010, 34:2090-2097.
57. Blesius A., Cassier P.A., Bertucci F., Fayette J., Ray-Coquard I., Bui B., et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 2011, 11:72.
58. Machlenkin S., Pinsk I., Tulchinsky H., Ziv Y., Sayfan J., Duek D., et al. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Colorectal Dis 2011, 13:1110-1115.
59. Rutkowski P., Nowecki Z., Nyckowski P., Dziewirski W., Grzesiakowska U., Nasierowska-Guttmejer A., et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006, 93:304-311.
60. Fiore M., Palassini E., Fumagalli E., Pilotti S., Tamborini E., Stacchiotti S., et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol 2009, 35:739-745.
61. Akiyoshi T., Oya M., Fujimoto Y., Kuroyanagi H., Ueno M., Yamaguchi T., et al. Complete resection after imatinib treatment of a gastrointestinal stromal tumor of the ileum with peritoneal metastases: report of a case. Surg Today 2010, 40:272-276.
62. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
63. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and effi cacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
64. Verweij J., van Oosterom A., Blay J.Y., Judson I., Rodenhuis S., van der Graaf W., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006-2011.
65. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Effi cacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
66. Blanke C.D., Demetri G.D., von Mehren M., Heinrich M.C., Eisenberg B., Fletcher J.A., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625.
67. Verweij J., Casali P.G., Zalcberg J., LeCesne A., Reichardt P., Blay J.Y., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
68. Blanke C.D., Rankin C., Demetri G.D., Ryan C.W., von Mehren M., Benjamin R.S., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008, 26:626-632.
69. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010, 28:1247-1253. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).
70. Blay J.Y., Le Cesne A., Ray-Coquard I., Bui B., Duffaud F., Delbaldo C., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007, 25:1107-1113.
71. Le Cesne A., Ray-Coquard I., Bui B.N., Adenis A., Rios M., Bertucci F., et al. French Sarcoma Group. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010, 11:942-949.
72. Hislop J, Mowatt G, Sharma P, Fraser C, Elders A, Jenkinson D, et al. Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. J Gastrointest Cancer, in press.
73. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
74. George S., Blay J.Y., Casali P.G., Le Cesne A., Stephenson P., Deprimo S.E., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45:1959-1968.